FAQ: Cybin Inc. CEO Transition and Company Overview
Summary
Cybin Inc. announced that Doug Drysdale stepped down as CEO effective September 2, 2025, with co-founder Eric So appointed as interim CEO while the board searches for a permanent replacement. This leadership change occurs as Cybin advances its clinical pipeline including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.
What is the main announcement in this press release?
Cybin Inc. announced that Doug Drysdale stepped down as CEO effective September 2, 2025, and co-founder Eric So has been appointed as interim CEO while the board searches for a permanent replacement.
When did the CEO transition take effect?
The CEO transition became effective on September 2, 2025.
Who is the new interim CEO and what is his background with Cybin?
Eric So, who is a co-founder and President of Cybin, has been appointed as interim CEO during the transition period.
What will Eric So focus on as interim CEO?
Eric So will focus on advancing Cybin’s clinical pipeline, including CYB003 and CYB004, and ensuring continuity during the leadership transition.
What is the board doing regarding permanent leadership?
The Board of Directors has formed a committee to conduct a search for a new permanent CEO to lead the company through commercialization.
What are CYB003 and CYB004, and what stages are they in?
CYB003 is a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, while CYB004 is a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder.
What special designation has CYB003 received?
CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Where is Cybin Inc. operational?
Cybin is operational in Canada, the United States, the United Kingdom, and Ireland.
Where can investors find the latest news and updates about Cybin?
The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
What type of company is Cybin and what is its focus?
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental health conditions.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 192223